DCC2789 |
Jak3-in Tricyclic-3 |
Novel irreversible selective JAK3 inhibitor through the covalent interaction with a Jak3 active-site cysteine |
|
DCC2790 |
Jak3-in-4 |
Novel Selective JAK3 Inhibitor with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket |
|
DCC2791 |
Jak3-in-5 |
Novel Selective JAK3 Inhibitor with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket |
|
DCC2792 |
Jak-in-1 |
Novel potent JAK1/2/3 inhibitor |
|
DCC2793 |
Jak-in-3 |
Novel potent JAK1/3 inhibitor, targeting JAK3 and JAK1 with IC 50 at 3nM and 5nM, respectively |
|
DCC2794 |
Jami1001a |
Novel positive allosteric modulator of AMPA receptor |
|
DCC2795 |
Jamunone M |
Novel anti-triple-negative breast cancer (anti-TNBC) agent with a high selectivity against BC cells over normal human cells, downregulating phosphatidylinositide 3-kinase (PI3K)/Akt pathway by suppressing protein-tyrosine phosphatase 1B (PTP1B) expression |
|
DCC2796 |
Janelia Fluor 526, Se |
Novel fluorogenic yellow fluorescent dye for use in self-labeling tag systems |
|
DCC2797 |
Jar1.39 |
Novel mitophagy inducer with therapeutic potential for Parkinson's disease, acting as light chain 3 (LC3) interactors, similar to cardiolipin or ceramide, triggering mitophagy via Pink1/Parkin |
|
DCC2798 |
jarid1b Demethylase Inhibitor |
Novel Inhibitor of Jumonji AT-Rich Interactive Domain 1B (JARID1B) Histone Demethylase |
|
DCC2799 |
Jasminine |
Natural naphthyridine alkaloid |
|
DCC2800 |
Jasplakinolide |
Potent inhibitor of the proliferation of PC3 prostate carcinoma cells |
|
DCC2801 |
Jbir-22 |
Natural Inhibitor for Protein−Protein Interaction of the Homodimer of Proteasome Assembly Factor 3 |
|
DCC2802 |
Jbir-59 |
Natural radical scavenger, inhibiting L-glutamate toxicity in neuronal hybridoma N18-RE-105 cells |
|
DCC2803 |
Jbp485 |
Inhibitor of renal transporters OAT1 and OAT3; Antihepatitis agent as a substrate for intestinal PEPT1 |
|
DCC2804 |
Jbp923 |
Natural anti-inflammatory agent, showing potential for the treatment of inflammatory bowel disease (IBD) |
|
DCC2805 |
Jbsnf-000567 |
Metabolite of JBSNF-000088 |
|
DCC2806 |
Jc1-40 |
Novel RORα activator, diminishing diethylnitrosamine-induced acute liver injury and repressing transcriptional expression of APPs such as CXCL1 and LCN2 in mice |
|
DCC2807 |
Jcp-170 |
Novel dose-dependent inhibitor of ABHD6 |
|
DCC2808 |
jcp174-alk |
JCP174 analog used for affinity purification of labeled targets |
|
DCC2809 |
jcp174-ia |
Negative control of JCP174 |
|
DCC2810 |
Jcp-265 |
Novel dose-dependent inhibitor of ABHD6 |
|
DCC2811 |
Jcp405 |
Covalent dual inhibitor of DPAP1 and DPAP3 |
|
DCC2812 |
Jcp410 |
Covalent dual inhibitor of DPAP1 and DPAP3 |
|
DCC2813 |
Jcp474 |
Novel potent inhibitor of Mpro |
|
DCC2814 |
Jcp678 |
Novel irriversable serine hydrolases inhibitor |
|
DCC2815 |
jd-5006 |
Peripheral Selective CB1 Receptor Antagonist |
|
DCC2816 |
Jesridonin |
Novel apoptosis inducer, significantly inhibiting tumor growth in the xenograft model |
|
DCC2817 |
Jfd00950 |
Novel human flap endonuclease 1 (FEN1) inhibitor with in vitro inhibition of flap cleavage activity as well as cytotoxic activity against a colon cancer cell line, DLD-1 |
|
DCC2818 |
Jg2-38 |
Novel inhibitor of the heat shock protein 70 (Hsp70) with anti-proliferative activity in breast and prostate cancer cells |
|